EyePoint finishes Phase 3 enrollment for DURAVYU in wet AMD; top-line data mid-2026

EyePoint, Inc.

LUCIA trial enrolled and randomized over 400 patients in seven months; total >800 across both trials.
Interim safety data consistent with prior DURAVYU trials; DSMC recommended continuation without protocol changes.
Topline 56-week data for LUGANO expected mid-2026; LUCIA data to follow shortly after.
DURAVYU is a sustained-release TKI for wet AMD; Phase 3 program aligned with FDA and EMA.
DURAVYU has been evaluated in over 190 patients across four trials with favorable safety profile.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.